Gain Therapeutics (GANX) Cash from Investing Activities (2020 - 2024)

Gain Therapeutics' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$43447.0 for Q4 2024.

• In Q4 2024, Cash from Investing Activities fell 101.38% year-over-year to -$43447.0; the TTM figure through Dec 2024 stood at $5.0 million (down 51.31% YoY), while the FY2024 annual figure was $5.0 million, down 51.31% from the prior year.
• Cash from Investing Activities for Q4 2024 stood at -$43447.0, down from -$1.0 in the prior quarter.
• The five-year high for Cash from Investing Activities was $3.1 million in Q4 2023, with the low at -$14.9 million in Q2 2022.
• The 5-year median for Cash from Investing Activities is -$3156.5 (2020), against an average of $15516.2.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 66066.32% in 2022, then soared 27026.26% in 2023.
• Gain Therapeutics' Cash from Investing Activities stood at -$14551.0 in 2020, then advanced by 23.73% to -$11098.0 in 2021, then soared by 1305.89% to $133830.0 in 2022, then soared by 2247.65% to $3.1 million in 2023, then slumped by 101.38% to -$43447.0 in 2024.
• Business Quant data shows GANX's Cash from Investing Activities at -$43447.0 in Q4 2024, -$1.0 in Q3 2024, and $2.0 million in Q2 2024.